Objective: Primitive neuroectodermal tumors (PNET) of the kidney are rare and highly aggressive malignancies. The purpose of our study was to present information about the management of patients with metastatic disease. Methods: The records of 2 patients (30–year–old female and 32–year–old male) with metastatic PNET of the kidney were reviewed and our data compared with the literature. Results: Neither clinical evaluation nor radiological methods allowed to distinguish PNET from renal cell carcinoma. Immunohistochemistry revealed strong positivity for CD99 in tumor 1 and weak positivity for NSE and vimentin in both tumors. In tumor 2, EWS/FLI1 translocation was detected by RT–PCR. Patient 1 underwent nephrectomy, seven cycles of polychemotherapy, two cycles of high–dose chemotherapy, autologous bone marrow rescue, radiotherapy of suspicious skeletal foci and is without evidence of recurrent disease 28 months after therapy. Patient 2 underwent six cycles of polychemotherapy, nephrectomy, high–dose chemotherapy with cyclophosphamide and abdominal radiotherapy. Because of relapse high–dose chemotherapy with stem cell rescue was not performed. He underwent three further cycles of polychemotherapy and died one year after diagnosis due to cerebral metastasis. Conclusions: The diagnosis of renal PNET must be considered in young patients with renal neoplasm, particularly those with advanced disease at presentation. Achieving exact diagnosis has important clinical consequences because polychemotherapy and high–dose chemotherapy may lead to dramatic tumor reduction or even complete remission.

1.
Stout AP: A tumor of the ulnar nerve. Proc NY Pathol Soc 1918;18:2–12.
2.
Meier VS, Kühne Th, Jundt G, Gudat F: Molecular diagnosis of Ewing tumors: improved detection of EWS/FLI–1 and EWS/ ERG chimeric transcripts and rapid determination of exon combinations. Diagn Mol Path 1998;7:29–35.
3.
Harms D: Soft tissue sarcomas in the Kiel Pediatric Tumor Registry. Curr Top Pathol 1995; 89:31–45.
4.
Mor Y, Nass D, Raviv G, Neumann Y, Nativ O, Goldwasser B: Malignant peripheral primitive neuroectodermal tumor of the kidney. Med Pediatr Oncol 1994;23:437–440.
5.
Chan YF, Llewellyn H: Intrarenal primitive neuroectodermal tumor. Br J Urol 1994;73: 326–327.
6.
Horiguchi Y, Nakashima Y, Ishii T, Hata J, Tazaki H: Primitive neuroectodermal tumor of the retroperitoneal cavity. Urology 1994;44: 127–129.
7.
Khan MS, Stewart RA, Vazir H, O’Brien A: Primitive neuroectodermal kidney tumor. Ulster Med J 1995;64:111–113.
8.
Furman J, Murphy WM, Jelsma PF, Garzotto MD, Marsh RD: Primary primitive neuroectodermal tumor of the kidney: Case report and review of the literature. Am J Clin Pathol 1996;106:339–344.
9.
Marley EF, Liapis H, Humphrey PA, Nadler RB, Siegel CL, Zhu X, Brandt JM, Dehner LP: Primitive neuroectodermal tumor of the kidney – another enigma: A pathologic, immunohistochemical, and molecular diagnostic study. Am J Surg Path 1997;21:354–359.
10.
Sheaff M, McManus A, Scheimberg I, Paris A, Shipley J, Baithun S: Primitive neuroectodermal tumor of the kidney confirmed by fluorescence in situ hybridization. Am J Surg Pathol 1997;21:461–468.
11.
Rodriguez–Galindo C, Marina NM, Fletcher BD, Parham DM, Bodner SM, Meyer WH: Is primitive neuroectodermal tumor of kidney a distinct entity? Cancer 1997;79:2243–2250.
12.
Herman TE, McAlister WH, Dehner LP: Peripheral primitive neuroectodermal tumor: Report of a case arising in the kidney. Pediatr Radiol 1997;27:620–621.
13.
Quezado M, Benjamin DR, Tsokos M: EWS/ FLI–1 fusion transcripts in three peripheral primitive neuroectodermal tumor of the kidney. Hum Pathol 1997;28:767–771.
14.
Fontaine C, Schots R, Braeckman J, Goossens A, Soete G, De Grève J: Long–term survival in an adult metastatic renal peripheral primitive neuroectodermal tumor (PPNET) with multimodality treatment including high–dose chemotherapy. Ann Oncol 1997;8:691–694.
15.
Antoneli CB, Costa CM, de Camargo B, Sredni ST, Alfer W Jr, Chojniak R: Primitive neuroectodermal tumor (PNET)/extraosseous Ewing sarcoma of the kidney. Med Pediatr Oncol 1998;30:303–307.
16.
Takeuchi T, Iwasaki H, Ohjimi Y, Ohshima K, Kaneko Y, Ischiguro M, Hiratsuka Y, Sakamoto K, Kikuchi M: Renal primitive neuroectodermal tumor: A morphologic, cytogenetic, and molecular analysis with the establishment of two cultured cell lines. Diagn Mol Pathol 1997;6:309–317.
17.
Parlorio E, Arrazola J, Pedrosa I, Ruiz MA: Primitive neuroectodermal tumor of the kidney. Am J Roengtenol 1998;171:1432–1433.
18.
Ranadive NU, Urmi C, Kumar M: Primitive neurorectodermal tumor (PNET) of the kidney: A case report. Arch Esp Urol 1999;52: 190–192.
19.
Amin HM, Candel AG, Husain AN: Pathologic quiz case: A 22–year–old man with an abdominal mass. Arch Pathol Lab Med 1999; 123:541–543.
20.
Delattre O, Zucman J, Melot T, Sastre Garau X, Zucker JM, Lenoir GM, Ambros PF, Sheer D, Turc–Carrel C, Triche TJ, Aurias A, Thomas G: The Ewing family of tumors: A subgroup of small–round–cell tumors defined by specific chimeric transcripts. N Engl J Med 1994;331: 294–299.
21.
Navarro S, Cavazzana AO, Llombart–Bosch A, Triche TJ: Comparison of Ewing’s sarcoma and peripheral neuroepithelioma. Arch Pathol Lab Med 1994;11:608–615.
22.
Kushner BH, Hajdu SI, Gulati SC, Erlandson RA, Exeelby PR, Lieberman PH: Extracranial primitive neuroectodermal tumors: The Memorial Sloan–Kettering Cancer Center experience. Cancer 1991;67:1825–1829.
23.
Miser J, Kinsella TJ, Triche TJ, Steis R, Tsokos M, Wesley R, Horvath K, Belasco J, Longo DL, Glatstein E: Treatment of peripheral neuroepithelioma in children and young adults. J Clin Oncol 1987;5:1752–1758.
24.
Israel M, Miser J, Triche TJ: Neuroepithelial tumors; in Pizzo PA, Poplack DG (ed): Pediatric Oncology. Philadelphia, Lippincott, 1989, vol 29, pp 923–934.
25.
Marina NM, Etcubanas E, Parham DM, Bowman LC, Green A: Peripheral PNET (peripheral neuroepithelioma) in children: A review of St. Jude experience and controversies in diagnosis and management. Cancer 1989;64:1952– 1960.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.